The Risk Of Persistent Local Disease In Bladder Cancer Patients Found To Be Pathologic Stage T0 At Radical Cystectomy

Main Category: Urology / Nephrology
Also Included In: Cancer / Oncology
Article Date: 01 Jul 2008 - 2:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


ORLANDO, FL (UroToday.com) - Pathologic stage T0 (pT0) rates following radical cystectomy (RC) alone range from 10-15%. The pT0 rate increases in patients that have received neoadjuvant platinum-based chemotherapy. Survival in patients that achieve pT0 status is significantly improved compared to patients with residual invasive disease. Increasingly clinicians are questioning the necessity for RC in patients that can be identified as pT0 in the bladder after chemotherapy.

While post-chemotherapy staging of the bladder is known, the risk of involvement of the pelvic lymph nodes (LNs) in these patients is less well documented. The authors sought to evaluate the status of the regional LNs in patients that have achieved pT0 status. Therefore, the authors evaluated the pathologic characteristics of patients with Tis-T4 disease on transurethral resection of the bladder tumor, but were pT0 at the time of radical cystectomy. They evaluated the LN status at time of radical cystectomy.

Out of 1,925 patients undergoing a RC between 1990 and 2008, 51 had received chemotherapy prior to RC and were pT0 at the time of surgery. The median LN count was 12 (range 1-51). None of the 33 patients receiving neoadjuvant chemotherapy and 33% of the 21 patients who had received chemotherapy prior to cystectomy for metastatic or locally advanced disease had lymph node metastases at the time of surgery.

The authors concluded that the regional LNs in the pT0 population remain a potential site of active disease in patients who received chemotherapy for locally advanced bladder cancer. The risk of LN metastases in patients who receive neoadjuvant chemotherapy for cT3 or less disease and are pT0 at time of surgery is very low.

Presented by Matthew G Kaag, MD, Guido Dalbagni, MD, Matthew Milowsky, MD, and Bernard H Bochner, MD, at the Annual Meeting of the American Urological Association (AUA) - May 17 - 22, 2008. Orange County Convention Center - Orlando, Florida, USA.

Reported by UroToday.com Contributing Editor David P. Wood, MD

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to: www.urotoday.com

Copyright © 2008 - UroToday

Article adapted by Medical News Today from original press release.
Visit our urology / nephrology section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Urotoday. "The Risk Of Persistent Local Disease In Bladder Cancer Patients Found To Be Pathologic Stage T0 At Radical Cystectomy." Medical News Today. MediLexicon, Intl., 1 Jul. 2008. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/113374.php>

APA
Urotoday. (2008, July 1). "The Risk Of Persistent Local Disease In Bladder Cancer Patients Found To Be Pathologic Stage T0 At Radical Cystectomy." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/113374.php.

Please note: If no author information is provided, the source is cited instead.


Urology / Nephrology

Most Popular Articles



Follow Our Urology News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Urology / Nephrology Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »